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Abstract
 
Bone marrow (BM)-derived professional antigen-presenting cells (pAPCs) are required for the
generation of cytotoxic T lymphocyte (CTL) responses to vaccinia virus and poliovirus. Fur-
thermore, these BM-derived pAPCs require a functional transporter associated with antigen
presentation (TAP). In this report we analyze the requirements for BM-derived pAPCs and
TAP in the initiation of CTL responses to lymphocytic choriomeningitis virus (LCMV) and
influenza virus (Flu). Our results indicate a requirement for BM-derived pAPCs for the CTL
responses to these viruses. However, we found that the generation of CTLs to one LCMV
epitope (LCMV nucleoprotein 396–404) was dependent on BM-derived pAPCs but, surpris-
ingly, TAP independent. The study of the CTL response to Flu confirmed the existence of this
BM-derived pAPC-dependent/TAP-independent CTL response and indicated that the TAP-
independent pathway is 
 
z
 
10–300-fold less efficient than the TAP-dependent pathway.
Key words: mice • lymphocytic choriomeningitis virus • inﬂuenza virus • T lymphocytes, 
cytotoxic • immunity, cellular
 
Introduction
 
CTLs are a major arm of the immune response responsible
for clearing viruses after they have infected cells. Fully dif-
ferentiated CTLs (effector cells) can recognize infected cells
and kill them, thereby eliminating sites of production and/
or persistence of virus. CTLs are able to recognize these
cells because they display fragments of viral proteins bound
to MHC class I molecules on the cell surface (1). Most of
these MHC class I–presented viral polypeptides are gener-
ated in the cytoplasm from the hydrolysis of viral proteins
synthesized by the infected cell. The antigenic peptides are
then transferred into the endoplasmic reticulum (ER)
 
1
 
 by
the transporter associated with antigen presentation (TAP)
transporter (2, 3). Newly synthesized MHC class I mole-
cules are assembled and retained in the ER. Upon binding
a peptide, the class I molecule is released and is transported
to the cell surface where it is displayed to the immune sys-
tem. This pathway is known as the endogenous or classical
MHC class I pathway (4).
We have recently examined how tissue-tropic viral in-
fections (i.e., those that infect nonhematopoietic cells but
not bone marrow [BM]-derived cells) stimulate precursor
CTLs to become CTL effectors. We found that although
nonhematopoietic cells infected with vaccinia or poliovirus
displayed viral peptides on their surface MHC class I mole-
cules, they were unable to initiate a CTL immune re-
sponse. Instead, the generation of these responses required
the presentation of the viral antigens by BM-derived pro-
fessional APCs (pAPCs), presumably dendritic cells or pos-
sibly macrophages (5). These cells are present in all tissues
wherein they acquire antigens and subsequently traffic to
lymph nodes where they present these antigens to specific
CD8
 
1 
 
T cells.
BM-derived pAPCs can acquire viral antigens in two
different ways. One is if they are infected with the virus. In
this case they present the viral antigens via the endogenous
MHC class I pathway. The second way is by internaliza-
tion of the viral antigens, which subsequently get pre-
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sented on class I molecules. This latter mechanism is
known as the exogenous MHC class I pathway or “cross
priming” (6). The exogenous MHC class I pathway was
shown to be the obligatory mechanism for generating CTL
responses to poliovirus infections of nonhematopoietic
cells (5).
The ability to take up and present exogenous antigens on
MHC class I molecules is largely limited to dendritic cells
and macrophages. Presentation of exogenous antigens on
MHC class I molecules can occur by two distinct mecha-
nisms. In one, the antigen is transferred from the endocytic
compartment into the cytosol where it is degraded into oli-
gopeptides. This mechanism requires the TAP transporter
to ferry peptide to class I molecules in the ER (7). This
pathway has been widely described in vitro, and is used for
the generation of CTLs to poliovirus infections of nonhe-
matopoietic cells in vivo (5). The second mechanism for
presenting exogenous antigens on MHC class I molecules
does not require the TAP transporter. In this situation, the
peptides are generated in the endocytic compartment and
somehow are acquired by class I molecule in this site or at
the cell surface. This mechanism has only been demon-
strated in vitro (8, 9), and it is unknown whether it is oper-
ative in in vivo situations.
Here we report new experiments to address the role of
BM-derived pAPCs in the CTL responses to lymphocytic
choriomeningitis virus (LCMV) and influenza virus (Flu).
Although our results confirm and generalize the notion that
BM-derived pAPCs are required for the generation of anti-
viral CTL responses, the results were surprising in as much
as TAP-independent antigen presentation by BM-derived
cells could readily be demonstrated for natural epitopes of
these two viruses
 
 
 
in vivo. To our knowledge, the results
reported here are the first to demonstrate that a TAP-inde-
pendent pathway can be functional in vivo. However, our
results also demonstrate that this TAP-independent path-
way of antigen presentation is much less efficient than the
TAP-dependent mechanism which, in vivo
 
,
 
 seems to be
the dominant pathway of MHC class I antigen presenta-
tion.
 
Materials and Methods
 
Cell Lines and Media.
 
EL4 (H-2
 
b
 
) and P815 (H-2
 
d
 
) cells were
obtained from American Type Culture Collection. These cells
were maintained in RPMI supplemented with 10% FCS, 2 mM
 
l
 
-glutamine, 50 
 
m
 
g/ml gentamicin, 0.01 M Hepes buffer, nones-
sential amino acids (all from Life Technologies), and 5 
 
3
 
 10
 
2
 
5
 
2-mercaptoethanol (Sigma-Aldrich).
 
Mice.
 
Mice were kept at the Animal Medicine Facility of the
University of Massachusetts Medical Center. All experiments
were performed under Institutional Animal Care and Use Com-
mittee–approved protocols.
 
Strains.
 
B6-Tap
 
1tp
 
 
 
1Arp
 
 (TAP
 
0/0
 
), C57BL/6 (B6), DBA2 (D2),
and (C57BL/6 
 
3
 
 DBA2)F1 (B6D2) mice were obtained from
The Jackson Laboratory at 6–8 wk of age.
 
Preparation of BM Chimeras.
 
To prepare chimeras, BM cells
from 6–15-wk-old donor mice were treated with anti-Thy 1 an-
tibody (M5/49.4.1; American Type Culture Collection) and
 
complement to eliminate mature T cells, washed twice, and re-
suspended in PBS. Recipient mice were irradiated with 600 rads
followed by a second irradiation with 500 rads 4 h later using a
GammaCell 40 apparatus (Nordion). Supralethally irradiated chi-
meras received a single dose of 1,300 rads. Irradiated mice were
reconstituted by intravenous inoculation of 4–6 
 
3
 
 10
 
6
 
 BM cells
from the different donors. To avoid rejection of donor MHC
class I–negative TAP
 
0/0
 
 cells by host NK cells, chimeras also re-
ceived an intraperitoneal injection of 10 
 
m
 
l rabbit anti–asialo
GM1 gammaglobulin (Wako Chemicals) on the day of the trans-
plant. This treatment was also employed in control chimeras re-
ceiving B6 BM. Chimeras were rested for 4–6 mo after reconsti-
tution to allow for complete elimination of host-derived pAPCs.
In some experiments double-irradiated chimeras were used.
These were prepared by subjecting chimeras (4 mo after the first
BM transplant) to a second irradiation and BM transplant.
 
Viruses and Peptides.
 
LCMV virus stocks (Armstrong strain,
4 
 
3
 
 10
 
5
 
 PFU/ml) were a gift from Dr. Raymond Welsh (Uni-
versity of Massachusetts Medical School, Worcester, MA). Flu
(A/PR8/34) was obtained as chicken alantoic fluid from infected,
embryonated eggs. The virus stock contained 4,860 hemaggluti-
nation units (HAU) per ml, in which 1 HAU was considered as
the dilution of virus stock (in 100 
 
m
 
l PBS) that agglutinated 50%
of human red blood cells (group O, factor Rh
 
1
 
) resuspended at a
concentration of 0.5% in 100 
 
m
 
l PBS. Both viruses were injected
intraperitoneally at the indicated doses in 0.5 ml PBS and killed 8
(LCMV) or 15–20 d (Flu) after infection.
To analyze responses to the different viruses, we used synthetic
versions of well-defined peptide epitopes. All of the peptides
were custom synthesized by Research Genetics. The purity and
identity of the peptides were determined by HPLC and mass
spectrometry. The Flu epitopes were Flu nucleoprotein (np)366–
374 (ASNENMETM [10]) and Flu np147–155 (TYQRTRALV
[10]), both derived from the np of A/PR/8/34. Flu np366–374 is
a D
 
b
 
-binding peptide and the major CTL epitope for A/PR/8/
34 in H-2
 
b
 
 mice. Flu np147–155 binds to K
 
d
 
 and is the immuno-
dominant epitope in H-2
 
d
 
 mice. As LCMV epitopes, we used
LCMV glycoprotein (gp)33–43 (KAVYNFATCGI [11]), LCMV
np396–404 (FQPQNGAFI [11]), LCMV gp276–278 (SGVEN-
PGGYCL [11]), and LCMV np118–126 (RPQASGVYM [12]).
LCMV gp33–43 is both D
 
b
 
 and K
 
b
 
 restricted, whereas LCMV
np396–404 is D
 
b
 
 restricted. These are the two immunodominant
epitopes in H-2
 
b
 
 mice. LCMV gp276–278 also binds to D
 
b
 
 but is
a subdominant epitope in H-2
 
b
 
 mice. LCMV np118–126 is an
L
 
d
 
-binding peptide and the immunodominant epitope in H-2
 
d
 
mice.
 
CTL Assays.
 
Effector cells consisted of freshly collected
spleen cells (LCMV) or spleen cells that had been restimulated in
vitro
 
 
 
for 5 d (Flu). For restimulation, 5 
 
3
 
 10
 
7
 
 spleen cells were
incubated in upright T25 tissue culture flasks (Falcon) with 1.5 
 
3
 
10
 
6 
 
EL4 or P815 cells that had been incubated with 1 
 
m
 
g/ml of
the appropriate Flu peptide and 50 
 
m
 
g/ml mitomycin C (Sigma-
Aldrich) for 1 h followed by extensive washing. CTL activity was
measured using 
 
51
 
Cr-release assays. In these assays, effector cells
were cultured with 6,000 Na
 
51
 
Cr-labeled target cells for 5 h at
the indicated E/T ratios in 200 
 
m
 
l complete RPMI. The percent-
age of killing was calculated using the formula: (experimental re-
lease 
 
2 
 
spontaneous release)/(full release 
 
2
 
 spontaneous release) 
 
3
 
100, in which spontaneous release was the count obtained when
targets cells were cultured in media in the absence of effector
cells, and full release when target cells were lysed with 1% Triton
X-100. Radioactivity was measured using a micro-beta tri-lux
system (Wallak). 
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Results
 
Role of BM-derived pAPCs in the Response to LCMV
Mice with TAP-deficient BM-derived Cells Generate CTL
Responses to LCMV.
 
To further investigate the role of
BM-derived pAPCs in the generation of immune responses
to viruses, we analyzed the presentation requirements to
generate CTLs to LCMV. We chose this virus because in
the mouse it induces extremely strong CTL responses. 8 d
after infection, at the peak of the CTL response, 
 
z
 
50–70%
of the splenic CD8
 
1 
 
T cells are virus specific in B6 animals
(13). Moreover, in contrast to viruses such as vaccinia and
vesicular stomatitis virus, CTL responses to LCMV do not
require B7-CD28 costimulation (data not shown, and ref-
erence 14). As B7 molecules are exclusively expressed on
BM-derived pAPCs, this latter finding raised the possibility
that other kinds of APCs might be capable of stimulating
anti-LCMV responses.
To analyze the role of BM-derived pAPCs with a func-
tional TAP in the response to viruses in vivo
 
,
 
 we made
TAP
 
0/0
 
®
 
B6 chimeras (BM donor
 
®
 
BM recipient). TAP
 
0/0
 
cells synthesize class I heavy and light chains normally, but
express extremely low levels of cell surface MHC class I
(both D
 
b
 
 and K
 
b
 
) because there are no peptides shuttled
from the cytosol to the ER. When BM from TAP
 
0/0
 
 mice
was transplanted into irradiated wild-type animals, the abil-
ity of the TAP
 
0/0
 
-derived cells to present antigen on MHC
class I through the traditional pathway remained impaired,
as evidenced by the marked reduction of cell surface MHC
class I in spleen cells (5, 15). However, CD8
 
1 
 
T cells devel-
oped normally and their numbers in the spleen of TAP
 
0/0
 
®
 
B6 chimeras were similar to those in control B6
 
®
 
B6
mice, because the TAP
 
0/0
 
 CD8
 
1 
 
T cells developed in the
recipient’s thymus where the radioresistant thymic epithe-
lial cells expressed normal levels of MHC class I (5, 15).
Moreover, we have shown previously that the CD8
 
1 
 
T
cells in the TAP
 
0/0
 
®
 
B6 chimeras respond to immunization
with wild-type dendritic cells pulsed with limiting amounts
of peptide at least as well as in B6
 
®
 
B6 mice; therefore, in
TAP
 
0/0
 
®
 
B6 chimeras there is no defect in the repertoire of
CD8
 
1
 
 T cells or in their responsiveness (5).
To analyze the role of BM-derived cells with a func-
tional TAP in the anti-LCMV CTL response, TAP
 
0/0
 
®
 
B6
and B6
 
®
 
B6 mice were infected with LCMV, and CTL
activity against two dominant epitopes (LCMV np396–404
and LCMV gp33–43) and one subdominant epitope
(LCMV gp276–286) was determined using peptide-pulsed
EL4 cells as targets. The results were surprising and in sharp
contrast with the results we reported previously for vac-
cinia virus. As seen in Fig. 1, freshly explanted spleen cells
from TAP
 
0/0
 
®
 
B6 or B6
 
®
 
B6 chimeras that had been in-
fected 8 d before effectively killed targets that had been in-
cubated with either LCMV np396–404 or LCMV gp33–
43. To a lesser degree, these spleen cells also killed targets
that had been pulsed with the subdominant epitope LCMV
gp276–278. Although the response by TAP
 
0/0
 
®
 
B6 mice
was in general somewhat lower than in controls, they still
generated strong CTL responses to LCMV. Similar results
 
were obtained when the CD8
 
1
 
 T cell responses were mea-
sured by IFN-
 
g
 
 intracellular staining of in vitro–restimu-
lated spleen cells (not shown).
Several hypotheses can explain these unexpected results:
(a) the CTL response to LCMV did not require MHC class
I presentation by BM-derived pAPCs; (b) the CTL re-
sponse to LCMV was dependent on BM-derived pAPCs,
but because LCMV is so efficient in inducing CTLs, the
few residual pAPCs of host origin were enough to drive
the CTL response; and (c) the CTL response to LCMV
was dependent on BM-derived pAPCs but the LCMV
peptides were presented in a TAP-independent manner.
We designed experiments to address each of these hypoth-
eses.
 
Double-irradiated TAP
 
®
 
B6 Chimeras Still Generate Re-
sponses to LCMV.
 
We attempted to test whether residual
host (wild-type) BM-derived pAPCs were responsible for
the anti-LCMV CTL response in the TAP
 
®
 
B6 chimeras
by using more rigorous procedures to eliminate these cells.
It has been reported that a second irradiation and BM
transplant into chimeras decreases the number of host- and
BM-derived cells to almost undetectable levels. Similar re-
sults can be achieved by supralethally irradiating recipient
mice (i.e., exposure to a single dose of 1,300 rads, instead
of the usual split dosages we normally used of 500
 
 1 
 
600
rads [16–18]). We made double-irradiated chimeras with
TAP
 
0/0
 
®
 
B6 recipients that were aged for 4 mo (to allow
turnover of pAPCs), reirradiated (500 
 
1 
 
600 rads), and re-
constituted again with BM similar to that of the original
donor. Supralethally irradiated chimeras were made with
B6D2 heterozygous recipients (homozygous mice do not
survive these high levels of irradiation). Fig. 2 shows that
Figure 1. TAP0/0®B6 chimeras infected with LCMV generate CTL
responses to dominant and subdominant LCMV epitopes. Chimeras
(three/group) of the type TAP0/0®B6 (left panels) and B6®B6 (right
panels) were infected with 4 3 103 PFU LCMV. 8 d later, mice were
killed and their spleen cells were used in 51Cr-release assays against the
targets indicated (right). Each line represents a single mouse. For each
group and target, identical symbols indicate the same mouse. 
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TAP
 
0/0
 
®
 
B6 double-irradiated chimeras infected with LCMV
generated strong CTL responses to LCMV np396–404 and
LCMV gp33–43 that were somewhat smaller than those of
B6
 
®
 
B6 mice. Also, both groups of mice developed weak
but detectable CTL responses to the subdominant epitope
LCMV gp276–286. Similar results were obtained when su-
pralethally irradiated chimeras were used (not shown).
These experiments indicate that further depletion of host
origin pAPCs does not inhibit the generation of CTLs in
TAP
 
0/0
 
®
 
B6 chimeric mice. However, these experiments
cannot completely rule out that a few residual host- and
BM-derived cells were driving the CD8
 
1
 
 T cell responses
in these mice.
 
BM-derived APCs Are Required in the CTL Response to an
LCMV Epitope.
 
To test the hypothesis that the anti-
LCMV CTL response in TAP
 
0/0
 
®
 
B6 chimeric mice was
due to TAP-independent antigen presentation, we gener-
ated chimeric mice with BM whose MHC molecules were
unable to present the LCMV epitopes.
Specifically, we constructed parent
 
®
 
F1 chimeras of the
type B6
 
®
 
B6D2, D2
 
®
 
B6D2, and control B6D2®B6D2.
If BM-derived pAPCs were required for the generation of
CTL responses, B6®B6D2 mice should only be responsive
to H-2b–restricted epitopes, D2®B6D2 should only be re-
sponsive to H-2d–restricted epitopes, and B6D2®B6D2
mice should be responsive to both H-2b– and H-2d–
restricted epitopes. We infected the parent®F1 chimeras
with LCMV, and 8 d later the animals were killed and their
spleen cells used in CTL assays against epitopes restricted to
H-2b or H-2d. The results in Fig. 3 show that D2®B6D2
mice, which do not express Db on BM-derived cells of do-
nor origin, failed to mount a CTL response to LCMV
np396–404. This was despite Db expression in non–
BM-derived cells. On the other hand, B6®B6D2
and B6D2®B6D2 controls (which express Db on both
BM-derived and non–BM-derived cells) generated strong
CTL responses to LCMV np396–404. The inability of
D2®B6D2 mice to generate CTLs to LCMV np396–404
was not due to a generalized CD81 T cell deficiency be-
cause they responded strongly to the Ld-restricted epitope
LCMV np118–126. These results demonstrate that BM-
derived pAPCs are required in the CTL response to
LCMV np396–404. Importantly, these results also show that
single-irradiated chimeras lack host (radioresistant) pAPCs
that can support the response to LCMV np396–404.
Therefore, the generation of CTLs to LCMV np396–404
in single, double, and supralethally irradiated TAP0/0®B6
chimeras as described above was not due to residual host-
and BM-derived cells but to a TAP-independent mecha-
nism of antigen presentation by donor-derived APCs.
Surprisingly, although the results for LCMV np396–404
were clear-cut, those for LCMV gp33–43 and LCMV
np118–126 were not. We found that at the relatively high
doses of LCMV we normally used (i.e., 4 3 103 PFU),
D2®B6D2 not only generated responses to the Ld-
Figure 2. Double irradiation does not abrogate the ability of TAP0/0
®B6 chimeras to generate CTL responses to LCMV epitopes. Double-
irradiated chimeras (three/group) of the type TAP0/0®B6 (left panels)
and B6®B6 (right panels) were infected with 4 3 103 PFU LCMV. 8 d
later, mice were killed and their spleen cells were used in 51Cr-release as-
says against the targets indicated (right). Each line represents a single
mouse. For each group and target, identical symbols indicate the same
mouse.
Figure 3. The CTL response to LCMV np396–404 is dependent on
antigen presentation by BM-derived cells. Chimeras (three/group) of the
type B6®B6D2 (left panels), D2®B6D2 (middle panels), and
B6D2®B6 D2 (right panels) were infected with 4 3 103 PFU LCMV. 8 d
later, mice were killed and their spleen cells were used in 51Cr-release as-
says against the targets indicated (right). Each line represents a single
mouse. For each group and target, identical symbols indicate the same
mouse.1147 Sigal and Rock
restricted LCMV np118–126, but also to the Db-restricted
LCMV gp33–43, albeit consistently lower than those gen-
erated by B6®B6D2 mice. Also, B6®B6D2 mice gener-
ated CTLs to the Ld-restricted LCMV np118–126 in single
and double-irradiated chimeras (not shown). This could in-
dicate that at high viral doses, residual pAPCs of host origin
are initiating the response to these two epitopes, or that for
these epitopes, nonhematopoietic cells are functioning as
pAPCs. We favor the first hypothesis because in additional
experiments with 200 PFU LCMV, the response to LCMV
gp33–43 was abrogated in D2®B6D2 but not in
B6®B6D2 chimeras (Fig. 4). In addition, experiments
with supralethally irradiated mice seem to indicate that re-
sidual host pAPCs are responsible for the CTL responses to
the high viral dose of LCMV. However, the health of the
mice was not optimal at the time of these experiments, and
we were unable to repeat the experiments a sufficient num-
ber of times to draw definitive conclusions on this point.
Role of BM-derived pAPCs in the Response to Flu
The CTL Response to Flu Is Dependent on BM-derived
pAPCs. To determine the role of BM-derived pAPCs in
the generation of CTLs to yet another virus, we decided to
examine Flu for which the CTL response has been well
characterized in the mouse (1). We inoculated B6®B6D2,
D®B6D2, and B6D2®B6D2 mice with 73 HAU Flu.
The results in the top panels of Fig. 5 clearly show that
D2®B6D2 mice, which did not express the Db-restricting
element on the BM-derived cells, did not generate CTLs
to the Db-restricted epitope Flu np366–374, despite ex-
pression of Db on the recipient’s nonhematopoietic cells.
The lack of response was not due to the inability of
D2®B6D2 mice to generate CTLs because they re-
sponded strongly to the Kd-restricted epitope Flu np147–
155 (Fig. 5, bottom row, center panel). This clearly dem-
onstrated the fundamental importance of BM-derived
pAPCs in the generation of CTLs to Flu np366–374. The
same groups of mice that were analyzed for the response to
Flu np366–374 were also analyzed for the response to the
Kd-restricted Flu np147–155 (Fig. 5, bottom panels).
B6D2®B6D2 and D2®B6D2 mice generated strong re-
sponses to this epitope. This was expected because they ex-
pressed Kd in the vast majority of BM-derived cells, which
were of donor origin. However, B6®B6D2 mice also gen-
erated CTL responses to Flu np147–155 despite the lack of
expression of Kd in most BM-derived cells. To investigate
whether this response was due to host- and BM-derived
pAPCs that resisted irradiation, we generated supralethally
irradiated chimeras (1,300 rads) of the types B6®B6D2
and B6D2®B6D2. The results in Fig. 6 show that suprale-
thally irradiated B6®B6D2 mice did not respond to Flu
np147–155 whereas B6D2®B6D2 mice did. This was not
due to the inability of supralethally irradiated B6®B6D2
mice to mount CTL responses because they generated de-
tectable responses to the Db-restricted Flu np366–374.
These results demonstrate that BM-derived cells are re-
quired for the generation of CTLs to multiple epitopes of
the Flu virus.
High Doses of Flu Generate CTLs That Are Dependent in a
BM-derived APC but TAP Independent. The results with
LCMV np396–404 indicated the existence of a TAP-inde-
pendent antigen presentation pathway that was operative in
vivo. However, we had previously not found this pathway
during vaccinia and poliovirus infection. Because LCMV is
a mouse pathogen and replicates very well in the mouse,
and vaccinia and poliovirus replicate in the adult mouse
much less extensively, we hypothesized that the ability to
generate CTLs in a TAP-independent fashion was at least
partly dependent on a high antigenic load. To look at the
Figure 4. At a low viral dose, the CTL response to LCMV gp33–41 is
dependent on antigen presentation by BM-derived cells. Chimeras
(three/group) of the type B6®B6D2 (left panels), D2®B6D2 (middle
panels), and B6D2®B6 D2 (right panels) were infected with 200 PFU
LCMV. 8 d later, mice were killed and their spleen cells were used in
51Cr-release assays against the targets indicated (right). Each line repre-
sents a single mouse. For each group and target, identical symbols indicate
the same mouse.
Figure 5. The CTL response to Flu np366–374 is depen-
dent on antigen presentation by BM-derived antigen-present-
ing cells. Chimeras (three/group) of the type B6®B6D2 (left
panels), D2®B6D2 (middle panels), and B6D2®B6D2 (right
panels) were infected with 73 HAU Flu A/PR8/34. CTL as-
says were performed with spleen cells that had been restimu-
lated in vitro as described in Materials and Methods. Targets
are as indicated. Each line corresponds to an individual mouse.
Similar figures within a group of chimeras correspond to the
same mouse (e.g., all squares in the B6®B6D2 group corre-
spond to the same mouse recognizing different targets).1148 Antigen Presentation in CTL Responses to Viruses
relationship of antigenic load and the use of different path-
ways of MHC class I antigen presentation during viral in-
fections in vivo, we investigated the role of TAP on BM-
derived pAPCs in the CTL response to graded doses of Flu.
This virus infects the mouse experimentally, but its ability
to replicate is much more restricted than LCMV’s. We in-
oculated TAP0/0®B6 chimeras or B6®B6 controls with
either 2.4 (data not shown), 24, or 73 HAU Flu (Fig. 7).
Mice were killed 15–20 d later and their spleen cells were
restimulated in vitro for 5 d with mitomycin C–treated
EL4 cells that had been incubated with Flu np366–374.
Whereas control B6®B6 chimeras generated strong re-
sponses to high and low viral doses, TAP0/0®B6 chimeras
failed to generate a CTL response to the Flu epitope at the
lower doses. Conversely, TAP0/0®B6 chimeras still gener-
ated CTL responses to Flu when the viral dose was in-
creased to 30 ml, albeit strongly diminished compared with
their B6®B6 counterparts. The inability of TAP0/0®B6
mice to generate responses at the lower dose and dimin-
ished responses at the higher dose could not be attributed
to an intrinsic defect of the CD81 T cell repertoire of these
mice because we and others have demonstrated previously
that TAP0/0®B6 mice generate CTL responses at least as
strong as B6®B6 mice when immunized with a virus con-
struct that bypasses TAP (5, 15) and when the number of
antigen-bearing APCs or the concentration of peptide at
the APC surface was a limiting factor (5). Therefore, the
results with Flu confirm those with LCMV above indicat-
ing that in vivo, BM-derived pAPCs can present antigen
independent of TAP function. However, this pathway re-
quired higher antigenic load than the classical TAP-depen-
dent pathway.
Discussion
In a previous report, we demonstrated that BM-derived
pAPCs are required for the initiation of antivaccinia and
antipolio CTL responses. In this report, we extend these
findings to demonstrate that BM-derived pAPCs are also
required in the CTL response to Flu and at least for two
LCMV epitopes (LCMV np396–404 and low doses of
LCMV gp33–43). Therefore, our results, together with the
demonstration by other investigators that CTL responses to
other antigens such as tumors, DNA vaccines, and bacteria
are also dependent on BM-derived pAPCs (19–26), indi-
cate a general requirement for BM-derived pAPCs in the
initiation of most, if not all primary CTL responses.
In the case of LCMV np118–126, we have been unable
to demonstrate a dependence on BM -derived APCs. Lenz
et al. (26) in this issue had similar results with this epitope.
From our combined data, it is possible to conclude that
nonhematopoietic cells can initiate CTL responses to
LCMV np118–126. However, it is more likely that a few
residual host pAPCs (probably ,1%) may be sufficient to
stimulate these CTL responses. LCMV replicates extremely
well in dendritic cells so that the few residual cells of host
origin may become infected and efficiently stimulate CTL
responses. Indeed, this is what we observe for CTL re-
sponses to Flu np147–155 in “single” versus supralethally
irradiated chimeras. Therefore, it is likely that with high
doses of LCMV, the few residual cells are still capable of
initiating almost wild-type responses to LCMV gp33–43
and LCMV np118–126, but not to LCMV np396–404.
The response to LCMV gp33–43 can be abrogated when
the viral dose is reduced, but the CTL response to LCMV
np118–126 remains. This difference between LCMV
Figure 6. The CTL response to Flu np147–155 in B6®B6D2 is abro-
gated by supralethally irradiating recipient mice. Supralethally irradiated
chimeras of the type B6®B6D2 (left panels; four animals) and
B6D2®B6D2 (right panels; five animals) were infected with 73 HAU
Flu A/PR8/34. CTL assays were performed with spleen cells that had
been restimulated in vitro as described in Materials and Methods. Targets
are as indicated. Each line corresponds to an individual mouse. Similar
figures within a group of chimeras correspond to the same mouse (e.g., all
squares in the B6®B6D2 group correspond to the same mouse recogniz-
ing different targets).
Figure 7. TAP0/0®B6 chimeras generate specific CTL responses to
high but not low doses of Flu. Chimeras of the type TAP0/0®B6 (left
panels) and B6®B6 (right panels) were infected with 24.3 (top panels;
three mice per group) or 73 (bottom panels; five mice per group) HAU
Flu A/PR8/34. CTL assays were performed with spleen cells that had
been restimulated in vitro as described in Materials and Methods. Targets
were Flu np366–374 pulsed EL4 cells (filled symbols) and EL4 targets
(open symbols).1149 Sigal and Rock
epitopes could be dependent on the efficiency of antigen
processing, peptide affinity for MHC class I, and/or
CD81 T cell precursor frequency. Earlier studies with
“parent®F1” chimeras (27) also support the concept that
BM-derived pAPCs are required for the generation of anti-
LCMV CTLs, even to the Ld-restricted epitope. Why the
results of these authors differ from ours in the response to
LCMV np118–126 is unclear. However, the disparity
might be attributed to different strains of LCMV and/or
different combinations of donor/recipient mouse strains, or
it may be that they measured the responses using LCMV-
infected targets rather than cells pulsed with the individual
CTL epitopes. Nonetheless, their results strongly support
our view that BM-derived pAPCs have a fundamental role
in CTL responses.
In this report we also demonstrate anti-Flu and anti-
LCMV CTL responses that are dependent on BM-derived
pAPCs but independent of TAP function. As CTL re-
sponses are not generated to LCMV np396–404 and Flu
np366–374 in chimeras reconstituted with H-2d BM, our
irradiation protocol has been sufficient to eliminate the host
pAPCs. Furthermore, we have found that peritoneal exu-
date macrophages obtained from TAP0/0®B6 mice are in-
capable of presenting a TAP-dependent epitope when in-
fected with a recombinant vaccinia virus (not shown).
Therefore, the generation of CTLs in TAP0/0®wild-type
chimeras is likely to be due to TAP-independent presenta-
tion by BM-derived pAPCs rather than by radioresistant
host (wild-type) pAPCs. Because LCMV np396–404 and
Flu np366–374 are derived from proteins that do not trans-
locate into the ER, these results are surprising and repre-
sent the first demonstration in vivo of TAP-independent
presentation of such epitopes that we are aware of.
There are two possible explanations for the TAP-inde-
pendent presentation of the LCMV and Flu epitopes. One
is that these peptides are transported by an alternate mecha-
nism from the cytosol into the ER of infected BM-derived
pAPCs. Although such a mechanism has been suggested for
an ER membrane protein (28), this seems to be excep-
tional, and in similar in vitro experiments TAP-indepen-
dent presentation has not been observed for the LCMV
and Flu epitopes (3, 29). The other explanation is that these
peptides do not require transport into the ER because they
are binding to class I molecules in another location. In
some cases, macrophages and dendritic cells can generate
class I–presented peptides from exogenous antigens in en-
docytic compartments (8, 9, 30). Our data do not distin-
guish between these mechanisms. However, because there
is abundant data that exogenous antigens do stimulate CTL
responses in vivo (6) and can be the major source of anti-
gen for generating CTL responses to a viral infection (5),
we favor this second interpretation.
The TAP-independent mechanism of CTL generation
appears to be substantially less efficient than the TAP-
dependent route. Between 10–300-fold more Flu is
needed to generate CTL responses in chimeras with TAP-
deficient BM compared with controls. Moreover, for other
viruses such as polio and vaccinia virus we fail to detect any
TAP-independent response, including situations in which
the CTL response is stimulated through the exogenous
pathway of class I antigen presentation. This may be be-
cause the viral load is too low to stimulate CTLs through
this pathway or because the antigenic epitopes fail to gen-
erate properly in the endocytic compartment. Although the
TAP-independent pathway of antigen presentation is less
efficient, it is likely to contribute to the generation of CTLs
at least in some infections with high viral loads.
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